endocannabinoid

Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.

ABSTRACT Moreover, THCV suppressed proliferation, and all phytocannabinoids exerted remarkable anti-inflammatory actions. Our data suggest that CBG and CBGV may have potential in the treatment of dry-skin syndrome, whereas CBC, CBDV and especially THCV show promise to become highly efficient, novel anti-acne agents. Moreover, based on their remarkable anti-inflammatory actions, phytocannabinoids could be efficient, yet …

Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Read More »

Jul 28 2019

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities

ABSTRACT Topical formulations that contain cannabinoid ligands (or that enhance the cutaneous ECS tone) could have therapeutic values in skin inflammations. Indeed, recently, a new drug containing PEA has been approved by the FDA for the treatment of dermatitis [70]. Moreover, a recent pilot study on 20 pediatric patients suffering from atopic dermatitis aimed to …

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities Read More »

Jun 29 2019

Q&A: medical marijuana (cannabis) and lupus

ABSTRACT There is only one currently ongoing study of medical marijuana for lupus. That study is looking at whether a potential new drug made from a synthetic cannabinoid can treat joint pain and swelling (inflammation) in people with lupus. The drug, which is called JBT-101 (lenabasum), doesn’t produce a high. Several smaller studies of other …

Q&A: medical marijuana (cannabis) and lupus Read More »

Jun 28 2019

Joints for joints: cannabinoids in the treatment of rheumatoid arthritis.

ABSTRACT Peripherally, cannabinoids show anti-inflammatory effects by activating cannabinoid type 2 receptors (CB2) which decrease cytokine production and immune cell mobilization. In contrast, cannabinoid type 1 receptor (CB1) activation on immune cells is proinflammatory while CB1 antagonism provides anti-inflammatory effects by increasing β2-adrenergic signaling in the joint and secondary lymphoid organs. In addition, the nonpsychotropic …

Joints for joints: cannabinoids in the treatment of rheumatoid arthritis. Read More »

Jun 26 2019

Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities

Q&A: medical marijuana (cannabis) and lupus

Joints for joints: cannabinoids in the treatment of rheumatoid arthritis.

JOIN OUR NEWSLETTER

CONNECT WITH US

About

LEARN

Shop

These statements have not been evaluated by the FDA. This product is not intended diagnose, treat, cure or prevent disease.